|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study显示文摘Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative patients.Here,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer.Methods:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 weeks.The primary endpoint was the objective response rate(ORR)assessed by an independent review committee.Secondary endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and safety.Results:Of 179 patients screened,125 were eligible and received RC48 treatment.The ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),respectively.The most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not RC48-related.Conclusions:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy. | Zhi Peng Tianshu Liu Jia Wei Airong Wang Yifu He Liuzhong Yang Xizhi Zhang Nanfeng Fan Suxia Luo Zhen Li Kangsheng Gu Jianwei Lu Jianming Xu Qingxia Fan Ruihua Xu Liangming Zhang Enxiao Li Yuping Sun Guohua Yu Chunmei Bai Yong Liu Jiangzheng Zeng Jieer Ying Xinjun Liang Nong Xu Chao Gao Yongqian Shu Dong Ma Guanghai Dai Shengmian Li Ting Deng Yuehong Cui Jianmin Fang Yi Ba Lin Shen | 2021 | Cancer Communications2021，41，11： | 29 |
| 2 | Semi-rigid thoracoscopy for undiagnosed exudative pleural effusions: a comparative study显示文摘背景 Thoracoscopy 为检测肋膜的流出高度敏感、精确。然而,很呼吸的医生不熟悉更普通的僵硬 thoracoscope 或灵活气管镜的使用,它是困难的在肋膜的洞以内操作。半硬的 thoracoscope 联合灵活、僵硬的仪器的最好的特征。因为有这台仪器的实践在中国是有限的,在为 undiagnosed exudative 的本地麻醉下面的半硬的 thoracoscopy (也就是医药的 thoracoscopy )的诊断用途肋膜的流出是在有 undiagnosed 的 50 个病人的 evaluated.Methods 肋膜的流出回顾地被学习,在2004年7月和2005年6月和剩余的之间的 23 收到的平淡的考试 27 个病人在2005年7月和2006年6月期间经历了医药 thoracoscopy 。肋膜的流出的平淡的考试包含了生物化学和细胞学,唾沫细胞学,和 thoracentesis。在诊断敏感的差别,与肋膜的液体检查和复杂并发症有关的费用在医药 thoracoscopy 揭示了的二 groups.Results 之间直接被比较在 6 个病人,的有结节的胸膜炎在 7 的腺癌,在 2 的有鳞房间的癌,在 3 的变形的癌,在 2 的间皮瘤, non-Hodgkin 在 1 的淋巴瘤,并且其它在 4 。仅仅 2 个病人不能变得明确诊断。医药 thoracoscopy 的诊断效率是 93%(25/27 ) 。仅仅 21% 病人在平淡的考试以后被诊断,包括在在 1 的 2 个病人,在 2 的肺癌症和未经决定的变形恶意的 parapneumonic 流出。有有结节的胸膜炎的 12 个病人被平淡的检查怀疑。与肋膜的流出测试有关的费用没显示出二个组(P=0.114 ) 之间的差别。在平淡的考试组的 23 个病人经历了 97 次 thoracentesis。二个肋膜的感染病人和 2 个气胸病人被鉴别并且接受抗菌素治疗和排水。医药 thoracoscopy 能被所有病人很好容忍。半硬的 thoracoscope 能被胸医生 casily 控制。最普通的复杂并发症从存在于的胸试管是短暂的胸疼痛(27 个病人中的 20 个) ,它将与常规止痛剂被管理。下的肺气肿的一个盒子和手术后的发烧的 2 个盒子是自我限制的。没有严重复杂并发症 occurred.Conclusions 医药 thoracoscopy 是一个简单、安全、划算的工具,与高积极的率。如果为医药 thoracoscopy 的设备是可得到的,医生们应该把它的存取递合适的病人。 | WANG Zhen TONG Zhao-hui LI Hong-jie ZHAO Ting-ting LI Xu-yan XU Li-li LUO Jing JIN Mu-lan LI Rui-sheng WANG Chen | 2008 | Chinese Medical Journal2008，，15： | 21 |
| 3 | Current status of diagnosis and treatment of bladder cancer in China-Analyses of Chinese Bladder Cancer Consortium database显示文摘Objective:To investigate current status of diagnosis and treatment of bladder cancer in China.Methods:A database was generated by Chinese Bladder Cancer Consortium(CBCC).From January 2007 to December 2012,14,260 cases from 44 CBCC centers were included.Data of diagnosis,treatment and pathology were collected.Results:The average age was 63.5 year-old and most patients were male(84.3%).The most common histologic types were urothelial carcinoma(91.4%),adenocarcinoma(1.8%),and squamous carcinoma(1.9%).According to 1973 and 2004 WHO grading system,42.0%,41.0%,and 17.0% of patients were grade 1,2,and 3,and 16.0%,48.7%,and 35.3% of patients were papillary urothelial neoplasms of low malignant potential,low,and high grade,respectively.Non-muscle invasive bladder cancer(NMIBC)and muscle invasive bladder cancer(MIBC)were 25.2% and 74.1%,respectively(0.8% not clear).Carcinoma in situ was only 2.4%.Most patients were diagnosed by white-light cystoscopy with biopsy(74.3%).Fluorescence and narrow band imaging cystoscopy had additional detection rate of 1.0% and 4.0%,respectively.Diagnostic transurethral resection(TUR)provided detection rate of 16.9%.Most NMIBCs were treated with TUR(89.2%).After initial TUR,2.6%accepted second TUR,and 45.7%,69.9%,and 58.7% accepted immediate,induced,and maintenance chemotherapy instillation,respectively.Most MIBCs were treated with radical cystectomy(RC,59.7%).Laparoscopic RCs were 35.1%,while open RC 63.4%.Extended and standard pelvic lymph node dissection were 7% and 66%,respectively.Three most common urinary diversions were orthotopic neobladder(44%),ileal conduit(31%),and ureterocutaneostomy(23%).Only 2.3% of patients accepted neo-adjuvant chemotherapy and only 18%of T3 and T4 patients accepted adjuvant chemotherapy.Conclusion:Disease characteristics are similar to international reports,while differences of diagnosis and treatment exist.This study can provide evidences for revisions of the guideline on bladder cancer in China. | Kaiwen Li Tianxin Lin 无 Wei Xue Xin Mu Enci Xu Xu Yang Fubao Chen Guangyong Li Lulin Ma Guoliang Wang Chaozhao Liang Haoqiang Shi Ming Li Mao Tang Xueyi Xue Yisong Lv Yaoliang Deng Chengyang Li Zhiwen Chen Xiaozhou Zhou Fengshuo Jin Xudong Liu Jinxin Wei Lei Shi Xin Gou Weiyang He Liqun Zhou Lin Cai Baiye Jin Guanghou Fu Xiangbo Kong Hongyan Sun Ye Tian Lang Feng Tiejun Pan Yiyi Wu Dongwen Wang Hailong Hao Benkang Shi Yaofeng Zhu Qiang Wei Ping Han Changli Wu Dawei Tian Zhangqun Ye Zheng Liu Zhiping Wang Junqiang Tian Lin Qi Minfeng Chen Wei Li Jinchun Qi Gongxian Wang Longlong Fu Zhaolin Sun Guangheng Luo Zhoujun Shen Zhaowei Zhu Jinchun Xing Zhun Wu Dong Wei Xin Chen Yanqun Na Hongfeng Guo Chunxi Wang Zhihua Lu Chuize Kong Yang Liu Jin Yang Jianyun Hu Xin Gao Jielin Li Changjun Yin Pu Li Shan Chen Zhen Du Jiongming Li Yongji Yan Xu Zhang Shuang Huang Fangjian Zhou Zhiling Zhang Yinghao Sun Shuxiong Zeng Song Cen Jiaquan Zhou Hanzhong Li Jin Wen Jian Huang | 2015 | Asian Journal of Urology2015，2，2： | 21 |
| 4 | Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients显示文摘 | ZHENG Ying CAI Guang-yan CHEN Xiang-mei FU Ping CHEN Jiang-hua DING Xiao-qiang YU Xue-qing LIN Hong-li LIU Jian XIE Ru-juan WANG Li-ning NI Zhao-hui LIU Fu-you YIN Ai-ping XING Chang-ying WANG Li SHI Wei LIU Jian-she HE Ya-ni DING Guo-hua LI Wen-ge WU Guang-li MIAO Li-ning CHEN Nan SU Zhen MEI Chang-lin ZHAO Jiu-yang GU Yong BAI Yun-kai LUO Hui-min LIN Shan CHEN Meng-hua GONG Li YANG Yi-bin YANG Xiao-ping LI Ying WAN Jian-xin WANG Nian-song LI Hai-ying XI Chun-sheng HAO Li XU Yan FANG Jing-ai LIU Bi-cheng LI Rong-shan WANG Rong ZHANG Jing-hong WANG Jian-qin LOU Tan-qi SHAO Feng-min MEI Feng LIU Zhi-hong YUAN Wei-jie SUN Shi-ren ZHANG Ling ZHOU Chun-hua CHEN Qin-kai JIA Shun-lian GONG Zhi-feng GUAN Guang-ju XIA Tian ZHONG Liang-bao | 2013 | Chinese Medical Journal2013，，12： | 16 |
| 5 | An efficient method to synthesize HMX by nitrolysis of DPT with N_2O_5 and a novel ionic liquid显示文摘A novel polyethylene glycol(PEG)-200-based dicationic acidic ionic liquid(PEG_(200)-DAIL) was used to synthesize HMX from DPT by nitrolysis with N_2O_5.It was found that either N_2O_5 or PEG_(200)-DAIL could improve the yield.Furthermore,the combined use of PEG_(200)-DAIL and N_2O_5 could increase the yield of HMX to 64%with the used quantity of HNO_3 decreased dramatically. | Hui Zhen Zhi Jun Luo Guang An Feng Chun Xu Lv | 2009 | Chinese Chemical Letters2009，20，4： | 15 |
| 6 | Fifty-eight cases of ocular ischemic diseases caused by carotid artery stenosis显示文摘背景到眼睛的血供应来自眼的动脉的网膜的中央脉管的系统和睫的脉管的系统。眼的动脉源自 ipsilateral 内部颈动脉动脉。如果吸藏或狭窄发生在颈动脉动脉,到眼的动脉的血灌注变得不够,导致前面、以后的眼睛的局部缺血的症状。学习是评估眼睛的 ischemic 疾病的临床的特征和风险因素的这的目的由颈动脉动脉 stenosis.Methods 引起了这研究是有颈动脉动脉狭窄的 145 个病人的回顾的评论。有形成的颈动脉动脉狭窄引起的眼睛的 ischemic 疾病的症状的 58 个病人组织 A 和仅仅有的颈动脉动脉狭窄形成了组 B 的另外的 87 个病人。我们分析了疾病,和相对风险因素的原因和功课,由比较在组 A 的颈动脉动脉狭窄的度是的二 groups.Results 比那高在组 B。并且组 A 有眼的动脉流动的更大的减少。男性,高血压, hyperlipidemia,并且吸烟显著地与颈动脉动脉狭窄有关。黑 fugax 是在组 A 的最普通的眼睛的症状。眼睛的 ischemic 疾病主要包括了 ischemic 眼的神经病, central/branch 网膜的动脉吸藏, ophthalmoplegia externa,和眼睛的 ischemic syndrome.Conclusions 颈动脉动脉有眼睛的 ischemic 疾病的狭窄相互关联。眼科医师必须为眼睛的症状观察,它是在一些病人的发作症状。 | LUO Rong-jiang LIU Shao-rui LI Xiao-min ZHUO Ye-hong TIAN Zhen | 2010 | Chinese Medical Journal2010，，19： | 14 |
| 7 | High-precision Dating and Geological Significance of Chang 7 Tuff Zircon of the Triassic Yanchang Formation, Ordos Basin in Central China显示文摘The Ordos Basin, as the second largest petroliferous basin of China, contains abundant oil and gas resources, oil shale, and sandstone-type uranium mineral resources. Chang 7 shale is not only the major source rock of the Mesozoic petroliferous system of the Basin, but is also crucial in determining the space-time distribution relationship of the shale section for the effective exploration and development of the Basin's oil and gas resources. To obtain a highly precise age of the shale development section, we collected tuff samples from the top and bottom profile of the Chang 7 Member, Yishi Village, Yaoqu Town, Tongchuan District, on the southern margin of the Ordos Basin and performed high-precision chemical abrasion(CA)–isotope dilution(ID)–thermal ionization mass spectrometry(TIMS) zircon U-Pb dating on the basis of extensive laser ablation inductively coupled plasma mass spectrometry(LA-ICP-MS) zircon U-Pb dating data. Our results show the precise ages of the top and bottom zircon in the Chang 7 shale to be 241.06±0.12 Ma and 241.558±0.093 Ma, respectively. We first obtained Chang 7 age data with Grade 0.1-Ma precision and then determined the age of the shale development in the Chang 7 Member to be the early-Middle Triassic Ladinian. This result is supported by paleontological evidence. The deposition duration of the Chang 7 shale is 0.5 Ma with an average deposition rate of the shale section being 5.3 cm/ka. Our research results provide time scale and basic data for further investigation of the basin–mountain coupling relation of the shale section, the sedimentary environment and volcanic ash and organic-matter-rich shale development relation, and the organism break-out and organic-matter enrichment mechanism. | ZHU Rukai CUI Jingwei DENG Shenghui LUO Zhong LU Yuanzheng QIU Zhen | 2019 | Acta Geologica Sinica(English Edition)2019，93，6： | 13 |
| 8 | Long non-coding RNA HULC as a diagnostic and prognostic marker of pancreatic cancer显示文摘BACKGROUND Long non-coding RNA(lncRNA)is abnormally expressed in various malignant tumors.In recent years,it has been found that IncRNA HULC is increasingly expressed in pancreatic cancer tissues and is involved in the development and progression of pancreatic cancer.However,the clinical value of serum HULC in pancreatic cancer remains unclear,and there are few studies on how HULC regulates the biological function of pancreatic cancer cells.AIM To determine the value of lncRNA HULC in the diagnosis and prognosis of pancreatic cancer,and its possible biological potential.METHODS Sixty patients with pancreatic cancer and sixty patients with benign pancreatic diseases admitted to Xiangya Hospital,Central South University were assigned to the pancreatic cancer group and the benign disease group,respectively,and another 60 healthy subjects were enrolled as the normal group during the same period.HULC-siRNA and NC-siRNA were transfected into pancreatic cancer cells.Quantitative real-time polymerase chain reaction was performed to determine the expression of HULC in tissues,serum,and cells.Western Blot was carried out to determine the expression ofβ-catenin,c-myc,and cyclin D1 in cells,and the cell counting kit-8,flow cytometry,and Transwell assay were conducted to determine the proliferation,apoptosis and invasion of cells.RESULTS Highly expressed in the tissues and serum of pancreatic cancer patients,HULC showed good clinical value in distinguishing between patients with pancreatic cancer,patients with benign pancreatic diseases and healthy subjects.HULC was related to pathological parameters including tumor size,T staging,M staging and vascular invasion,and the area-under-the-curve for evaluating these four expression of HULC had a significantly higher 3-year overall survival(OS)and 5-year OS than those with high expression.T staging,M staging,vascular invasion,and HULC were independent prognostic factors affecting the 3-year OS of patients with pancreatic cancer.Inhibition of HULC expression prevented the proliferation and invasion of pancreatic cancer cells,promoted apoptosis,and inhibited the expression of Wnt/β-catenin signaling pathway-related proteins,β-catenin,c-myc,and cyclin D1.The Wnt/β-catenin signaling pathway agonist(LiCl)restored proliferation,apoptosis,and invasion of pancreatic cancer cells with inhibited expression of HULC.CONCLUSION HULC is an effective marker for the diagnosis and prognosis of pancreatic cancer,which may affect the biological function of pancreatic cancer cells through the Wnt/β-catenin signaling pathway. | Zheng-Lin Ou Zhen Luo Ye-Bin Lu | 2019 | World Journal of Gastroenterology2019，25，46： | 13 |
| 9 | Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome显示文摘PRKAG2 心脏的症候群正染色体的主导的继承疾病在编码 γ 的 PRKAG2 基因从变化被结果;激活安培的蛋白质 kinase 的 2 规章的子单元。影响病人通常开发室的 tachyarrhythmia 并且经历对医疗倔强并且要求心脏的移植的进步的心失败。在这研究,我们与家庭 Wolff-Parkinson-White 症候群从病人在 PRKAG2 识别一个 H530R 变化。由产生转基因的 H530R PRKAG2 和敲门在里面老鼠,我们证明两个模型包括心脏的肥大和肝糖存储概括人的症状,证实 H530R 变化是有原因地与 PRKAG2 有关心脏的症候群。我们进一步联合联系 adeno 的 virus-9 (AAV9 ) 和 CRISPR/Cas9 编辑基因的系统当让野类型的等位基因未经触动时,破坏编码 H530R 的变异的 PRKAG2 等位基因。在出生后的白天的 AAV9-Cas9/sgRNA 的单个全身的注射 4 或白天 42 实质地在转基因的 H530R PRKAG2 和敲门在里面鼠标恢复心的形态学和函数。一起,我们的工作建议在 vivo CRISPR/Cas9,染色体编辑由有选择地破坏引起疾病的变化是在 PRKAG2 心脏的症候群和另外的主导的继承心脏病的治疗的一个有效工具。 | Chang Xie Ya-Ping Zhang Lu Song Jie Luo Wei Qi Jialu Hu Danbo Lu Zhen Yang Jian Zhang Jian Xiao Bin Zhou Jiu-Lin Du Naihe Jing Yong Liu Yan Wang Bo-Liang Li Bao-Liang Song Yan Yan | 2016 | Cell Research2016，26，10： | 12 |
| 10 | Validation of the chinese version of the EORTC QLQ-CR29 in patients with colorectal cancer显示文摘AIM To assess the validity and reliability of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer 29(EORTC QLQ-CR29) in Chinese patients with colorectal cancer(CRC). METHODS From March 2014 to January 2015, 356 patients with CRC from four different hospitals in China were enrolled in the study, and all patients self-administered the EORTC QLQ-CR29 and the quality of life core questionnaire(EORTC QLQ-C30). Evaluation of the scores was based on the Karnofsky Performance Scale(KPS). The reliability and validity of the questionnaires were assessed by Cronbach's α coefficient, the Spearman correlation test and Wilcoxon rank sum test.RESULTS The EORTC QLQ-CR29 showed satisfactory reliability(α > 0.7), although the urinary frequency and blood and mucus in stool dimensions had only moderate reliability(α = 0.608). The multitrait scaling analyses showed good convergent(r > 0.4) and discriminant validity. Significant differences were obtained for each item in the different KPS subgroups(KPS ≤ 80; KPS > 80). body image and most single-item dimensions showed statistically significant differences in patients with a stoma compared with the rest of the patients. CONCLUSION The EORTC QLQ-CR29 exhibits high validity and reliability in Chinese patients with CRC, and can therefore be recommended as a valuable tool for the assessment of quality of life in these patients. | Jin-bo Lin Lei Zhang Dong-Wen Wu Zhou-Huan xi xue-Jun Wang Yun-Shou Lin Wakana Fujiwara Jing-Ru Tian Min Wang Peng Peng Ai Guo Zhen Yang Le Luo Ling-Ya Jiang Qia-Qia Li xue-Ying Zhang Yun-Feng Zhang Hou-Wei xu bing Yang xun-Lin Li Yi-xiong Lei | 2017 | World Journal of Gastroenterology2017，23，10： | 12 |
| 11 | Comparison of long-term clinical outcome between transcatheter Amplatzer occlusion and surgical closure of isolated patent ductus arteriosus显示文摘专利 ductus artertiosus (PDA ) 的背景 Transcatheter Amplatzer 吸藏作为外科的闭合的一种最低限度地侵略的选择出现了。这研究的目标是比较在二个过程之间的长期的临床的结果,特别在长期的剩余分流上,迟了或很晚过程相关的复杂并发症,并且有 4 公里的一条最小的直径的 PDA 从2000年1月对待到2003年7月的肺的高血压和总数 255 病人孤立的左室的 dilation.Methods A 的回归在这研究被包括并且被跟随了在上面直到2008年7月。病人根据病人的家被分到设备或外科的闭合组或他们的父母是偏爱。基线物理考试,胸X光线照相术, electrocardiography ,和 echocardiography 是执行 preprocedure ,在每 follow-up.Results , 72 个病人接受了 transcatheter 过程( Group-TC ), 183 为 PDA 经历了外科的操作(组织这样)闭合,组们在他们的人口分布是类似的,外科手术前的临床的 characteristics.There 不是心脏的死亡,象传染心内膜炎和 Amplatzer 管 occluder (忙乱)那样的迟了的复杂并发症在也逐出 grou 更多的尖锐过程相关的复杂并发症与 Group-TC (1.4%)(P=0.004 ) 相比在组织这样(13.7%) 被记录。恢复时间是(8.7 瑲牥潩?吗?? | CHEN Zhao-yang WU Li-ming LUO Yu-kun LIN Chao-gui PENG Ya-fei ZHEN Xing-chun CHEN Liang-long | 2009 | Chinese Medical Journal2009，，10： | 10 |
| 12 | Modified culotte stenting for treatment of complex coronary bifurcation lesions: immediate and 9-month outcomes in a pilot study显示文摘背景为冠的分叉损害(CBL ) 的治疗的最佳的 stenting 策略仍然保持不明确。现在的学习观察了技术可行性和可靠性,9月临床并且在有 drug-eluting stents.Methods A 的 CBL 的治疗的修改 culotte stenting ( MCS )的 angiographic 结果与要求了 stenting 的 CBL 34 个连续病人总计父母容器( PV ),主要分支( MB )和方面分支( SB )被包括。所有病人首先被分配为 CBL 干预收到 MCS (每 MCS ),并且可能被换到在时间地尖锐的分支吸藏的情况下收到 double-kissing-crush stenting ( DKS )(每协议) .Results 立即的 angiographic 或程序的成功在 33/34 (97%)被完成损害(病人)每 MCS , 34/34 (100%)损害(病人)每有百分之百成功的最后的汽球吻的协议。在 9 个月的长期的临床的成功每 MCS 是 94% 并且 94% 每协议,仅仅 2 个病人有咽峡炎的出现,但是任何一个都不他们需要目标损害 revascularization。没有过程相关的 biomarker 举起,没有 in-stent 血栓 peri-procedurally 并且在 9 月的后续。在 9 个月的量的冠的 angiography 数据显示出那 in-stent (6%) 或二进制狭窄是的在里面片断(6%) 很少发生、最小的腔直径显著地被减少,但是迟了的腔损失是可接受的与仅仅(0. | CHEN Liang-long FAN Lin CHEN Zhao-yang ZHEN Xing-chun LUO Yu-kun LIN Chao-gui PENG Ya-fei | 2011 | Chinese Medical Journal2011，，13： | 10 |
| 13 | Olmutinib(HM61713) reversed multidrug resistance by inhibiting the activity of ATPbinding cassette subfamily G member 2 in vitro and in vivo显示文摘Overexpressing of ATP-binding cassette(ABC) transporters is the essential cause of multidrug resistance(MDR), which is a significant hurdle to the success of chemotherapy in many cancers.Therefore, inhibiting the activity of ABC transporters may be a logical approach to circumvent MDR.Olmutinib is an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI), which has been approved in South Korea for advanced EGFR T790 M-positive non-small cell lung cancer(NSCLC). Here,we found that olmutinib significantly increased the sensitivity of chemotherapy drug in ABCG2-overexpressing cells. Furthermore, olmutinib could also increase the retention of doxorubicin(DOX) and rhodamine 123(Rho 123) in ABC transporter subfamily G member 2(ABCG2)-overexpressing cells. In addition, olmutinib was found to stimulate ATPase activity and inhibit photolabeling of ABCG2 with [^(125) I]-iodoarylazidoprazosin(IAAP). However, olmutinib neither altered ABCG2 expression at protein and m RNA levels nor blocked EGFR, Her-2 downstream signaling of AKT and ERK. Importantly,olmutinib enhanced the efficacy of topotecan on the inhibition of S1-MI-80 cell xenograft growth. All the results suggest that olmutinib reverses ABCG2-mediated MDR by binding to ATP bind site of ABCG2 and increasing intracellular chemotherapeutic drug accumulation. Our findings encouraged to further clinical investigation on combination therapy of olmutinib with conventional chemotherapeutic drugs in ABCG2-overexpressing cancer patients. | Zhiqiang Zhang Xiaoran Guo Kenneth K.W.To Zhen Chen Xiaona Fang Min Luo Chunling Ma Jianhua Xu Shirong Yan Liwu Fu | 2018 | Acta Pharmaceutica Sinica B2018，8，4： | 9 |
| 14 | Abnormal expression of bHLH3 disrupts a flavonoid homeostasis network,causing differences in pigment composition among mulberry fruits显示文摘Mulberry fruits with high concentrations of anthocyanins are favored by consumers because of their good taste,bright color,and high nutritional value.However,neither the regulatory mechanism controlling flavonoid biosynthesis in mulberry nor the molecular basis of different mulberry fruit colors is fully understood.Here,we report that a flavonoid homeostasis network comprising activation and feedback regulation mechanisms determines mulberry fruit color.In vitro and in vivo assays showed that MYBA-bHLH3-TTG1 regulates the biosynthesis of anthocyanins,while TT2L1 and TT2L2 work with bHLH3 or GL3 and form a MYB-bHLH-WD40(MBW)complex with TTG1 to regulate proanthocyanidin(PA)synthesis.Functional and expression analyses showed that bHLH3 is a key regulator of the regulatory network controlling mulberry fruit coloration and that MYB4 is activated by MBW complexes and participates in negative feedback control of the regulatory network to balance the accumulation of anthocyanins and proanthocyanidins.Our research demonstrates that the interaction between bHLH3 and MYB4 in the homeostasis regulatory network ensures that the fruits accumulate desirable flavonoids and that this network is stable in pigmentrich mulberry fruits.However,the abnormal expression of bHLH3 disrupts the balance of the network and redirects flavonoid metabolic flux in pale-colored fruits,resulting in differences in the levels and proportions of anthocyanins,flavones,and flavonols among differently colored mulberry fruits(red,yellow,and white).The results of our study reveal the molecular basis of the diversity of mulberry fruit colors. | Han Li Zhen Yang Qiwei Zeng Shibo Wang Yiwei Luo Yan Huang Youchao Xin Ningjia He | 2020 | Horticulture Research2020，7，1： | 8 |
| 15 | Malnutrition and Quality of Life in Chinese Cancer Patients: a Clinical Study of 23,994 Subjects显示文摘Background Malnutrition is common in patients with cancer,and can negatively impact their quality of life(QoL)and even survival.However,there is currently no large data available on the prevalence of malnutrition in Chinese cancer patients.This study evaluated the prevalence of malnutrition and the QoL of Chinese patients with locoregional,recurrent or metastatic cancer.Methods We conducted a nationwide observational,multi-center,hospital-based cross-sectional study within the Chinese Society of Nutritional Oncology(CSNO)Network.All of the patients were diagnosed with one of the following 18 different types of malignant tumors:lung cancer,gastric cancer,liver cancer,colorectal cancer,breast cancer,esophageal cancer,cervical cancer,endometrial cancer,nasopharyngeal carcinoma,malignant lymphoma,leukemia,pancreatic cancer,ovarian cancer,prostate cancer,bladder cancer,brain cancer,biliary tract malignant tumors or gastrointestinal stromal tumors.These patients were enrolled from 72 hospitals located in different regions of China.The patients’nutritional status was evaluated based on the body mass index(BMI),loss of bodyweight,laboratory measurements and patient generated-subjective global assessment(PG-SGA)scores.The cancer patients’physical status and QoL were assessed by the Karnofsky Performance Status(KPS)questionnaire and the European Organization for Research and Treatment of Cancer(EORTC)QLQ-C30 questionnaire,respectively.Results From December 2013 to April 2016,23,994 patients hospitalized for cancer treatment(such as surgery,chemotherapy or radiotherapy)were enrolled in the study.The patients included 12,494(52.9%)males and 11,124(47.1%)females.The mean age was 55.8±13.7 years.The proportions of patients in cancer stagesⅠ,Ⅱ,Ⅲ,Ⅳand uncertain were 11.5%,20.3%,27.5%,30.2%and 10.5%,respectively.Among the 23,994 inpatients,the proportions of patients who were underweight(BMI<18.5 kg/m2),normal(18.5 kg/m2 | Hong Xia Xu Chun Hua Song Zhen Ming Fu Chang Wang Zeng Qing Guo Yuan Lin Ying Ying Shi Wen Hu Yi Ba Su Yi Li Zeng Ning Li Kun Hua Wang Jing Wu Ying He Jia Jun Yang Cong Hua Xie Fu Xiang Zhou Xin Xia Song Gong Yan Chen Wen Jun Ma Su Xia Luo Zi Hua Chen Ming Hua Cong Hu Ma Chun Ling Zhou Wei Wang Qi Luo Yong Mei Shi Yu Mei Qi Hai Ping Jiang Wen Xian Guan Jun Qiang Chen Jia Xin Chen Yu Fang Lan Zhou Yong Dong Feng Rong Shao Tan Tao Li Jun Wen Ou Qing Chuan Zhao Jian Xiong Wu Min Weng Qing Hua Yao Jiu Wei Cui Wei Li Han Ping Shi the Investigation on Nutrition Status and Clinical Outcome of Common Cancers(INSCOC)Group | 2021 | Journal of Nutritional Oncology2021，6，1： | 8 |
| 16 | Procalcitonin could be a reliable marker in differential diagnosis of post-implantation syndrome and infection after percutaneous endovascular aortic repair显示文摘 | Xue Ling Luo Songyuan Luo Jianfang Liu Zhen Gu Mengnan Kang Huiyuan Yang Fan Nie Bingrong Liu Yuan Huang Wenhui Xie Nianjin He Pengcheng Dong Haojian Ni Zhonghan Fan Ruixin Chen Jiyan | 2014 | Chinese Medical Journal2014，，14： | 8 |
| 17 | An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma显示文摘No clinically available biomarkers can predict pathological complete response(pCR)for esophageal squamous cell carcinomas(ESCCs)with neoadjuvant chemoradiotherapy(nCRT).Considering that antitumor immunity status is an important determinant for nCRT,we performed an integrative analysis of immune-related gene profiles from pretreatment biopsies and constructed the first individualized immune signature for pCR and outcome prediction of ESCCs through a multicenter analysis.During the discovery phase,14 differentially expressed immune-related genes(DEIGs)with greater than a twofold change between pCRs and less than pCRs( | Chaoqi Zhang Guochao Zhang Nan Sun Zhen Zhang Liyan Xue Zhihui Zhang Haijun Yang Yuejun Luo Xiaoli Zheng Yonglei Zhang Yufen Yuan Ruixue Lei Zhaoyang Yang Bo Zheng Le Wang Yun Che Feng Wang Sihui Wang Shugeng Gao Qi Xue Yi Zhang Jie He | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 7 |
| 18 | Validity of the Chinese Version of the Patient-Generated Subjective Global Assessment (PG-SGA) in Lung Cancer Patients显示文摘The prevalence of malnutrition is high among oncology patients in China. Although the Patient- Generated Subjective Global Assessment (PG-SGA) is widely recognized as an important nutritional assessment tool, it has not been validated for Chinese cancer patients. The purpose of this study was to conduct an analysis of nutrition screening and assessment data to validate the Chinese version of the PG-SGA in Chinese patients with lung cancer. This was an observational, cross-sectional study of 2,000 consecutive adult patients with lung cancer treated at several tertiary hospitals in China. Anthropometric and patient descriptive data were collected. The PG-SGA generated a score for the nutritional risk and a global rating for the nutritional status. The internal consistency, external consistency, and construct validity were evaluated, and a known-groups comparison and principal component analyses were conducted to evaluate the reliability and validity of the PG-SGA. The known-groups comparison demonstrated the ability of the PG-SGA to differentiate lung cancer patients of different nutritional and body mass index (BMI) groups. A confirmatory factor analysis supported the original four-factor structure of the PG-SGA. In terms of the internal and external consistency, the PG-SGA demonstrated intra-class correlation coefficients (ICC) up to 0.987. Alternative form validity was also demonstrated between Box 4 of the PG-SGA and the Karnofsky Performance Status score, with excellent external consistency (r = 0.972, P < 0.001). The construct validity was supported, and selected questionnaire dimensions were evident in the principal component analysis. Significant Spearman correlations (P < 0.001) were demonstrated. The Chinese version of the PG-SGA demonstrated significant reliability and sufficient exploratory properties to support its validity. It seems to be a valid tool that can be used to access the nutritional status of Chinese lung cancer patients. The validity of the PG-SGA in Chinese cancer patients warrants further investigation in other cancer types. | Zhen Ming Fu Hong Xia Xu Chun Hua Song Wei Li Zeng Qing Guo Yuan Lin Ying Ying Shi Wen Hu Yi Ba Su Yi Li Zeng Ning Li Kun Hua Wang Jing Wu Ying He Jia Jun Yang Cong Hua Xie Xin Xia Song Gong Yan Chen Wen Jun Ma Su Xia Luo Zi Hua Chen Ming Hua Cong Hu Ma Chun Ling Zhou Wei Wang Qi Luo Yong Mei Shi Yu Mei Qi Hai Ping Jiang Wen Xian Guan Jun Qiang Chen Jia Xin Chen Yu Fang Lan Zhou Yong Dong Feng Rong Shao Tan Tao Li Jun Wen Ou Qing Chuan Zhao Jian Xiong Wu Chang Wang Han Ping Shi The Investigation on Nutrition Status and Clinical Outcome of Common Cancers (INSCOC) Group | 2016 | Journal of Nutritional Oncology2016，1，1： | 7 |
| 19 | CONTINUUM TOPOLOGY OPTIMIZATION FOR MONOLITHIC COMPLIANT MECHANISMS OF MICRO-ACTUATORS显示文摘为分布式的顺从的机制的结构的拓扑学优化的一个多客观的计划处于 MEMS 状况微致动器在这个工作,机械灵活性和结构的僵硬在是看作客观功能的两个被介绍。这样开发的 Thecompliant 微观机构不能仅仅提供足够的产量工作而且有足够的刚硬抵抗反应力量并且当保持 thework 片时,维持它的形状。过滤途径的密度也被建议绞链在产生 mechanisms.SIMP 发生消除象棋盘,连接的网孔相关性和一个节点那样的数字不稳定性被用作插值计划显示材料模量的依赖调整 onelement 的密度。顺序的凸的编程方法例如动人的渐近线(MMA ) 的方法,被用来解决优化问题。介绍方法论的确认被一个典型数字例子表明。 | Luo Zhen Du Yixian Chen Liping Yang Jingzhou Karim Abdel-Malek | 2006 | Acta Mechanica Solida Sinica2006，19，1： | 6 |
| 20 | Silencing MYH9 blocks HBx-induced GSK3βubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma显示文摘MYH9 has dual functions in tumors.However,its role in inducing tumor stemness in hepatocellular carcinoma(HCC)is not yet determined.Here,we found that MYH9 is an effective promoter of tumor stemness that facilitates hepatocellular carcinoma pathogenesis.Importantly,targeting MYH9 remarkably improved the survival of hepatocellular carcinoma-bearing mice and promoted sorafenib sensitivity of hepatocellular carcinoma cells in vivo.Mechanistic analysis suggested that MYH9 interacted with GSK3βand reduced its protein expression by ubiquitin-mediated degradation,which therefore dysregulated theβ-catenin destruction complex and induced the downstream tumor stemness phenotype,epithelial–mesenchymal transition,and c-Jun signaling in HCC.C-Jun transcriptionally stimulated MYH9 expression and formed an MYH9/GSK3β/β-catenin/c-Jun feedback loop.X protein is a hepatitis B virus(HBV)-encoded key oncogenic protein that promotes HCC pathogenesis.Interestingly,we observed that HBV X protein(HBX)interacted with MYH9 and induced its expression by modulating GSK3β/β-catenin/c-Jun signaling.Targeting MYH9 blocked HBX-induced GSK3βubiquitination to activate theβ-catenin destruction complex and suppressed cancer stemness and EMT.Based on TCGA database analysis,MYH9 was found to be elevated and conferred poor prognosis for hepatocellular carcinoma patients.In clinical samples,high MYH9 expression levels predicted poor prognosis of hepatocellular carcinoma patients.These findings identify the suppression of MYH9 as an alternative approach for the effective eradication of CSC properties to inhibit cancer migration,invasion,growth,and sorafenib resistance in HCC patients.Our study demonstrated that MYH9 is a crucial therapeutic target in HCC. | Xian Lin Ai-min Li Yong-Hao Li Rong-Cheng Luo Yu-Jiao Zou Yi-Yi Liu Chen Liu Ying-Ying Xie Shi Zuo Zhan Liu Zhen Liu Wei-Yi Fang | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 6 |
您所在的机构暂未开通此部分的功能，请联系管理员